Skip to main content
. 2013 Sep 6;8(9):e73579. doi: 10.1371/journal.pone.0073579

Table 6. Sensitivity of QFT-GIT calculated over the total of patients tested (indeterminate results included as negative results) and only over the interpretable results (indeterminate results excluded) in PTB patients stratified by HIV status according to smear microscopy status.

Indeterminate results included as negative results Indeterminate results excluded
AFB-positive AFB-negative P (AFB- negative versus AFB -positive) AFB-positive AFB-negative P (AFB- negative versus AFB -positive)
Positive over total % (95% CI)
HIV-infected 12/19 14/19 12/12 14/17
63.2 (38.4–83.4) 73.7 (48.8–90.9 0.7281 100.0 (73.5–100) 82.4 (56.6–96.2) 0.2463
HIV-uninfected 43/46 10/12 43/44 10/12
93.5 (82.1–98.6) 83.3 (51.6–97.9) 0.2735 97.7 (88.0–99.9) 83.3 (51.6–97.9) 0.1127
Total 55/65 24/31 55/56 24/29
84.6 (73.5–92.4) 77.4 (58.8–90.4) 0.4031 98.2 (90.5–99.9) 82.8 (64.2–94.2) 0.0163

Footnotes: QFT-GIT: QuantiFERON® Gold in Tube; TB: Tuberculosis; HIV: Human Immunodeficiency Virus, AFB: Acid Fast Bacilli.